Planet Signs 7-Figure Contract Expansion with the German Government, Enabling Land and Water Management from Space
BERLIN--(BUSINESS WIRE)-- Planet Labs Germany GmbH, a leading provider of daily data and insights about Earth, today announced the German Federal Ministry of the Interior and Community (BMI) and the German Federal Agency for Cartography and Geodesy (BKG) have signed a seven-figure contract with Planet with a one year term and an option to renew for two more years.
The deal includes a fixed rate of all of Planet's data products over Germany, including insights from Planetary Variables, water monitoring services from Planet's partner EOMAP and access to Planet's Insights Platform. This data will inform a variety of use cases, including monitoring water, forests, agriculture, socio-economics, and land-use, and support federal monitoring campaigns and environmental assessments.
'Germany's topography is incredibly diverse, including agricultural land, forests, rivers and mountains, making Planet's broad area monitoring capabilities invaluable to understand daily changes,' said Martin Polak, Managing Director of Planet Labs Germany GmbH. 'BKG recognized this opportunity and has since demonstrated the value of centralized EO data to support initiatives across different federal agencies.'
Since the partnership began in November 2021, employees of all federal institutions have direct access to Planet insights, enabling them to streamline workflows and reduce expenses. Users are all German Federal Government entities and select federal state entities.
'Planet's near-daily data is key to inform ministries across the German government, including the Ministry of the Interior and Community and the Ministry of Food and Agriculture,' said Julia Kluge, Section Head of the Federal Service Point of Remote Sensing at BKG. 'By centralizing this data within one institution, all federal organizations benefit from the insights to inform their individual projects. This is a success story, increasing resource-sharing, reducing costs and ensuring all agencies have access to critical daily insights about our changing planet.'
Germany continues to be a key market for Planet, with its European headquarters based in Berlin. This expansion continues Planet's growth across the public and private sectors in Germany, demonstrating the importance of space-based data in government and corporate decision-making.
About Planet
Planet Labs Germany GmbH is part of the Planet group and is based at Planet's European headquarters in Berlin. Planet Labs PBC (NYSE: PL) is the parent company of the Planet group with global headquarters in San Francisco, USA. Planet is a leading provider of global, daily satellite imagery and geospatial solutions. Planet is driven by a mission to image the world every day, and make change visible, accessible and actionable. Founded in 2010 by three NASA scientists, Planet designs, builds, and operates the largest Earth observation fleet of imaging satellites. Planet provides mission-critical data, advanced insights, and software solutions to approximately 1,000 customers, comprising the world's leading agriculture, forestry, intelligence, education and finance companies and government agencies, enabling users to simply and effectively derive unique value from satellite imagery. Planet Labs PBC is a public benefit corporation listed on the New York Stock Exchange as PL. To learn more visit www.planet.com and follow us on X (formerly Twitter) or tune in to HBO's 'Wild Wild Space'.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
8 minutes ago
- Business Wire
JCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global Website
HYOGO, Japan--(BUSINESS WIRE)-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; 'JCR'), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the launch of its new global website. As the company turns 50, it is marking its growing footprint in Japan, the U.S., Europe, and Latin America with a unique website tailored for global audiences that reflects its passion for both science and humanity and brings the JCR brand to life for patients, physicians, and partners worldwide. 'At JCR, we are committed to advancing science and delivering on the treatments for patients with unmet needs around the world,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'In September, we celebrate the 50 th anniversary of the company I founded in 1975. The launch of our new global website reflects our evolution from an innovative startup in Japan to a global biopharmaceutical company. We remain dedicated to developing therapies for people with rare and genetic diseases and partnering with those who share our vision of transforming care for patients and families living with once untreatable diseases.' The site features streamlined user interface and curated content for patients, physicians, partners, and investors – reinforcing JCR's commitment to bridge the gap between complex science and unmet needs of patients and families. For the past 50 years, JCR has built a reputation for the development of innovative new therapeutic approaches, including its more recent J-Brain Cargo ® technology, a proprietary blood-brain barrier-penetrating technology that can deliver biotherapeutics into the central nervous system (CNS). This platform underpins several investigational pre-clinical and clinical staged therapies in JCR's pipeline, beginning with lysosomal storage disorders (LSDs), and it reflects the company's ongoing commitment to advancing treatments for CNS-related diseases across neurodegeneration, neuro-inflammation, and neuro-oncology conditions. JCR continues to strengthen its global research, development, and manufacturing capabilities, with a focus on addressing unmet medical needs and expanding therapeutic possibilities. Learn more about JCR, its technologies, and clinical development programs on its global website: About the J-Brain Cargo ® Platform Technology JCR Pharmaceuticals has developed a proprietary blood-brain barrier-penetrating technology, J-Brain Cargo ®, to bring biotherapeutics into the central nervous system. The first drug developed based on this technology and approved in Japan for the treatment a lysosomal storage disorder is IZCARGO ® (INN: pabinafusp alfa). About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world's most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including employees, partners, and patients. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit the global website:
Yahoo
22 minutes ago
- Yahoo
Citi upgrades Invitation Homes, downgrades American Homes 4 Rent on valuation gap
--Citi upgraded Invitation Homes (NYSE:INVH) to Buy and downgraded American Homes (NYSE:AMH) 4 Rent to Neutral, citing relative valuation and expectations that Invitation Homes' earnings growth will soon catch up with its peer. Citi said the recent underperformance of INVH shares, about 6% behind American Homes since first-quarter results, has widened the valuation gap to an attractive entry point. INVH now trades at a roughly 30 basis point implied cap rate discount to AMH, which Citi sees as near the lower end of historical levels. 'We believe INVH is in a good position to assess these risks given its knowledge of BTR rents and valuations in the market,' the analysts wrote, adding that INVH's guidance appears more conservative and may beat expectations on occupancy and rent growth. Citi sees additional upside from INVH's new lending program, which could add 7 cents to annual earnings, about a 3.5% boost, over the medium term. The initiative also opens up more opportunities to acquire built-to-rent communities from homebuilders. Despite slower lease growth in recent months, Citi expects both INVH and AMH to grow rents at around 4% over the next few years. While AMH may have already peaked in new lease growth in May, the bank noted that differences in rent trends were modest and likely driven by methodology and market reaction to seasonality. Citi raised its price target on INVH to $38.50 from $35, implying a 4.8% cap rate and a 19x multiple on 2026 core FFO. It maintained a $41 target for AMH, equating to a 4.7% cap rate and a 21x multiple. We continue to like the single-family rental sector overall, Citi said, but sees greater upside in INVH due to potential earnings reacceleration and a return to more typical relative valuation. Related articles Citi upgrades Invitation Homes, downgrades American Homes 4 Rent on valuation gap Melius upgrades Deere on long-term tech moat and recurring revenue upside UAE's data center project with U.S. tech firms faces security concerns Sign in to access your portfolio
Yahoo
22 minutes ago
- Yahoo
Why Nucor Stock Jumped 10% This Week
New tariffs could drive steel prices higher. Nucor has invested billions to grow its earnings power. The steel company should see a surge in free cash flow as capital projects ramp up operations. 10 stocks we like better than Nucor › Not every investor wants to invest in a cyclical sector. But it can be an important addition to a well-diversified portfolio. Nucor (NYSE: NUE) is the largest pure-play steel and steel products company in North America. While it is most commonly thought of as more of an income stock than a growth stock, shares popped as much as nearly 12% at one point this week. The stock has now moved off a three-year low it hit in early April. That was aided by the 10% surge it has made this week as of early Friday morning, according to data provided by S&P Global Market Intelligence. This week's move came after President Donald Trump announced the doubling of steel tariffs to 50% and officially implemented that raised level on June 4. That could be a meaningful move for the leading domestic steel company. Nucor has poured more than $10 billion into growth investments over the past five years. Many of those projects are just beginning to contribute to earnings. Two important projects will also begin ramping up operations later this year. Its largest current project -- a new greenfield sheet mill in West Virginia -- is expected to complete construction by the end of next year. That makes it a good time to look at an investment in Nucor. It looks to be near the bottom of a free-cash-flow cycle with capital spending beginning to decrease in coming years as those investments start generating revenue. Nucor generated over $8 billion in free cash flow in 2022 and another $5 billion in 2023. It dropped to negative $495 million in the first quarter, though. That could mark a point close to the bottom if the U.S. economy continues to grow. The tariffs supporting steel prices will only reinforce the strength in Nucor's business. Investors may be sensing a turn for this cyclical stock with the tariff catalyst. That helps explain the outsize move in Nucor stock this week. Before you buy stock in Nucor, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nucor wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,395!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $858,011!* Now, it's worth noting Stock Advisor's total average return is 997% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Howard Smith has positions in Nucor. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Nucor Stock Jumped 10% This Week was originally published by The Motley Fool
